Immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: results from a prematurely discontinued randomized multicenter trial
- Authors
- Park, Soohyung; Rha, Seung-Woon; Choi, Byoung Geol; Cho, Jang Hyun; Park, Sang Ho; Lee, Jin Bae; Kim, Yong Hoon; Park, Sang Min; Choi, Jae Woong; Park, Ji Young; Shin, Eun-Seok; Lee, Jae Beom; Suh, Jon; Chae, Jei Keon; Choi, Young Jin; Jeong, Myung Ho; Cha, Kwang Soo; Lee, Seung Wook; Kim, Ung; Kim, Gi Chang; Choi, Woong-Gil; Cho, Yun-Hyeong; Cho, Deok-kyu; Ahn, Jihun; Suh, Soon-Yong; Choi, Se Yeon; Byun, Jae Kyeong; Cha, Jin Ah; Hyun, Soo Jin; Kim, Ji Bak; Choi, Cheol Ung; Park, Chang Gyu
- Issue Date
- May-2023
- Publisher
- Mosby Inc.
- Citation
- American Heart Journal, v.259, pp 58 - 67
- Pages
- 10
- Journal Title
- American Heart Journal
- Volume
- 259
- Start Page
- 58
- End Page
- 67
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22354
- DOI
- 10.1016/j.ahj.2023.01.020
- ISSN
- 0002-8703
1097-6744
- Abstract
- Background We aimed to compare clinical outcomes between immediate and staged complete revascularization in primary percutaneous coronary intervention (PCI) for treating ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD).Methods A total of 248 patients were enrolled in a prospective, randomized, and multicenter registry. Immediate revas-cularization was defined as one-time PCI of culprit and non-culprit lesions at the initial procedure. Staged revascularization was defined as PCI of non-culprit lesions at a later date (mean, 4.4 days; interquartile range, 1-11.4), following initial cul-prit revascularization. The end points were major adverse cardiovascular events (MACE; composite of total death, recurrent myocardial infarction, and revascularization), any individual components of MACE, cardiac death, stent thrombosis, and stroke at 12 months.Results During a follow-up of 1 year, MACE occurred in 12 patients (11.6%) in the immediate revascularization group and in 8 patients (7.5%) in staged revascularization group (hazard ratio [HR] 1.60, 95% confidence interval [CI] 0.65- 3.91). The incidence of total death was numerically higher in the immediate group than in the staged group (9.7% vs 2.8%, HR 3.53, 95% CI 0.97-12.84); There were no significant differences between the 2 groups in risks of any individual component of MACE, cardiac death, stroke, and in-hospital complications, such as need for transfusion, bleeding, acute renal failure, and acute heart failure. This study was prematurely terminated due to halt of production of everolimus-eluting stents (manufactured as PROMUS Element by Boston Scientific, Natick, Massachusetts).Conclusions Due to its limited power, no definite conclusion can be drawn regarding complete revascularization strategy from the present study. Further large randomized clinical trials would be warranted to confirm optimal timing of complete revascularization for patients with STEMI and MVD. (Am Heart J 2023;259:58-67.)
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Clinical Pathology > 1. Journal Articles
- College of Medicine > Department of Internal Medicine > 1. Journal Articles
- College of Medicine > Department of Internal Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.